|
|
Rusty L. Montgomery, Matthew J. Potthoff, Michael Haberland, Xiaoxia Qi, Satoshi Matsuzaki, Kenneth M. Humphries, James A. Richardson, Rhonda Bassel-Duby, Eric N. Olson
J Clin Invest. 2008;
118(11):3588
doi:10.1172/JCI35847
Abstract |
Full text
| PDF
| Supplemental material

H
istone deacetylase (HDAC) inhibitors show remarkable therapeutic potential for a variety of disorders, including cancer, neurological disease, and cardiac hypertrophy. However, the specific HDAC isoforms that mediate their actions are unclear, as are the physiological and pathological functions of individual HDACs in vivo. To explore the role of Hdac3 in the heart, we generated mice with a conditional Hdac3 null allele. Although global deletion of Hdac3 resulted in lethality by E9.5, mice with a cardiac-specific deletion of Hdac3 survived until 3–4 months of age. At this time, they showed massive cardiac hypertrophy and upregulation of genes associated with fatty acid uptake, fatty acid oxidation, and electron transport/oxidative phosphorylation accompanied by fatty acid–induced myocardial lipid accumulation and elevated triglyceride levels. These abnormalities in cardiac metabolism can be attributed to excessive activity of the nuclear receptor PPARα. The phenotype associated with cardiac-specific Hdac3 gene deletion differs from that of all other Hdac gene mutations. These findings reveal a unique role for Hdac3 in maintenance of cardiac function and regulation of myocardial energy metabolism.
Citation information
This citation data is accumulated from CrossRef, which receives citation information from participating publishers, including this journal.
Not all publishers participate in CrossRef, so this information is not comprehensive.
Additionally, data may not reflect the most current citations to this article,
and the data may differ from citation information available from other sources
(for example, Google Scholar, Web of Science, and Scopus).
Total citations by year
in CrossRef
Citations to this article
in CrossRef
(23)
| Title and authors |
Publication |
Year |
Therapeutic Potential for HDAC Inhibitors in the Heart
Timothy A. McKinsey
|
Annu. Rev. Pharmacol. Toxicol.
|
2012 |
Multiple roles of class I HDACs in proliferation, differentiation, and development
Nina Reichert, Mohamed-Amin Choukrallah, Patrick Matthias
|
Cell. Mol. Life Sci.
|
2012 |
Epigenetics and Cardiovascular Development
Ching-Pin Chang, Benoit G. Bruneau
|
Annu. Rev. Physiol.
|
2012 |
Histone Deacetylase Inhibitors in Cell Pluripotency, Differentiation, and Reprogramming
Androniki Kretsovali, Christiana Hadjimichael, Nikolaos Charmpilas
|
Stem Cells International
|
2012 |
Tapping the brake on cardiac growth-endogenous repressors of hypertrophic signaling-
Joost J. Leenders, Yigal M. Pinto, Esther E. Creemers
|
Journal of Molecular and Cellular Cardiology
|
2011 |
Mitochondrial adaptations to physiological vs. pathological cardiac hypertrophy
E. D. Abel, T. Doenst
|
Cardiovascular Research
|
2011 |
Epigenetic regulation in neural crest development
Yifei Liu, Andrew Xiao
|
Birth Defect Res A
|
2011 |
High expression of liver histone deacetylase 3 contributes to high-fat-diet-induced metabolic syndrome by suppressing the PPAR-γ and LXR-α-pathways in E3 rats
Dongmin Li, Xuan Wang, Wuchao Ren, Juan Ren, Xi Lan, Feimiao Wang, Hongmin Li, Fujun Zhang, Yan Han, Tianbao Song, Rikard Holmdahl, Shemin Lu
|
Molecular and Cellular Endocrinology
|
2011 |
Histone Deacetylase Inhibitors in the Treatment of Hematological Malignancies and Solid Tumors
Mario Federico, Luigi Bagella
|
Journal of Biomedicine and Biotechnology
|
2011 |
Merits of Non-Invasive Rat Models of Left Ventricular Heart Failure
Alex P. Carll, Monte S. Willis, Robert M. Lust, Daniel L. Costa, Aimen K. Farraj
|
Cardiovasc Toxicol
|
2011 |
|